A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season

Clinical Infectious Diseases

Volumn 55, Issue 3, 2012, Pages 332-342

  Skowronski, Danuta M ^a,b   Janjua, Naveed Z ^a,b   De Serres, Gaston ^e,f   Winter, Anne Luise ^g   Dickinson, James A ^c   Gardy, Jennifer L ^a,c   Gubbay, Jonathan ^g,i   Fonseca, Kevin ^c,h,j   Charest, Hugues ^e   Crowcroft, Natasha S ^g,i,k   Fradet, Monique Douville ^e   Bastien, Nathalie ^l   Li, Yan ^l,m   Krajden, Mel ^a,d   Sabaiduc, Suzana ^a   Petric, Martin ^a,d  

^a PROVINCIAL HEALTH SERVICES AUTHORITY   (Canada)

^b Centre for Health Services and Policy Research   (Canada)

^c Department of Microbiology and Immunology ^*  (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g PUBLIC HEALTH ONTARIO   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j Alberta Provincial Laboratory   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^m UNIVERSITY OF MANITOBA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIGENICITY; CANADA; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; EPIDEMIC; HUMAN; INFANT; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PHYLOGENY; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NASOPHARYNX; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84863973361     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis431     Document Type: Review

References (40)

1. Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005. Can Commun Dis Rep 2005; 31:181-91.
2. Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25:2842-51.
3. Skowronski DM, De Serres G, Dickinson J, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 2009; 199:168-79.
4. Janjua NZ, Skowronski DM, De Serres G, et al. Estimates of influenza vaccine effectiveness for 2007-08 from Canada's sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis 2012; doi:10.1093/infdis/jis283.
5. Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med 2010; 7:e1000258.
6. Skowronski DM, Janjua NZ, De Serres G, et al. Effectiveness of AS03-adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. Br Med J 2011; 342:c7297.
7. Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010; 10:71.
8. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-7.
9. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004.
10. Cowling BJ, Ng S, Ma ESK, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 2011; 51:1370-79.
11. Skowronski DM, Janjua NZ, Hottes TS, De Serres G. Mechanism for seasonal vaccine effect on pandemic H1N1 risk remains uncertain. Clin Infect Dis 2011; 52:831-2.
12. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis 2012; 12:36-44.
13. National Advisory Committee on Immunization. Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2010-2011. Can Commun Dis Rep 2010; 36:1-49.
14. Bush RM, Bender CA, Subbarao K, Cox NJ, Fitch WM. Predicting the evolution of human influenza A. Science 1999; 286:1921-5.
15. Broemeling AM, Watson DE, Prebtani F. Population patterns of chronic health conditions, co-morbidity and healthcare use in Canada: implications for policy and practice. Healthcare Quarterly 2008; 11:70-6.
16. Statistics Canada. Influenza immunization in less than one year. table 105-0501-health indicator profile, annual estimates, by age group and sex, Canada, provinces, territories, health regions (2007 boundaries) and peer groups, occasional, CANSIM (database). Available at : http://www5.statcan.gc.ca/ cansim/a01?lang=eng. Accessed 5 November 2011.
17. Gilmour H, Hofmann N. H1N1 vaccination. Health Reports 2010; 21:1-7. Available at : http://www.statcan.gc.ca/pub/82-003-x/2010004/article/11348-eng. pdf. Accessed 5 November 2011.
18. Russel KL, Burke R. Influenza surveillance and VE in the DoD 2010-2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/Vaccines andRelatedBiologicalProductsAdvisoryCommittee/UCM246395.pdf. Accessed 5 November 2011.
19. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 2011; 9:669-83.
20. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2011-12 northern hemisphere influenza season. Available at: http://www.who.int/influenza/vaccines/virus/2011-12north/en/index.html. Accessed 5 November 2011.
21. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012 southern hemisphere influenza season. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/2012south/en/. Accessed 5 November 2011.
22. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. PNAS 1999; 96:14001-6.
23. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccineinduced protection. J Infect Dis 2011; 204:1879-85.
24. Jackson LA. Using surveillance to evaluate influenza vaccine effectiveness. J Infect Dis 2009; 199:155-8.
25. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/ 201202-recommendation.pdf. Accessed 12 March 2012.
26. Simonsen L, Clarke MJ, Schonberger LB, et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998; 178:53-60.
27. Bansal S, Pourbohloul B, Hupert N, et al. The shifting demographic landscape of pandemic influenza. PLoS One 2010; 5:e9360.
28. Skowronski DM, Hottes TS, Janjua NZ, et al. Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. CMAJ 2010; 182:1851-56.
29. Bolotin S, Pebody R, White PJ, et al. A new sentinel surveillance system for severe influenza in England shows a shift in age distribution of hospitalized cases in the post-pandemic period. PLoS One 2012; 7:e30279.
30. Hillaire ML, van Trierum SE, Kreijtz JH, et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 2011; 92:2339-49.
31. Gilca R, Deceuninck G, De Serres G, et al. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children. Pediatrics 2011; 128:e1084-91.
32. Mahmud S, Hammond G, Elliott L, et al. Effectiveness of the panxdemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine 2011; 29:7975-81.
33. Ortqvist A, Berggren I, Insulander M, et al. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 2011; 52:1203-11.
34. Pebody R, Hardelid P, Fleming DM, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/Euro Surveill. 2011;16(6):pii= 19791. Available at: http://www. eurosurveillance.org/ ViewArticle.aspx?ArticleId=19791. Accessed 5 November 2011.
35. Savulescu C, Jiménez-Jorge S, de Mateo S, et al. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. Euro Surveill 2011; 16:pii= 19820. Available at: http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=19820. Accessed 5 November 2011.
36. Kissling E, Valenciano M; I-MOVE Case-Control Studies Team. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Euro Surveill 2011; 16: pii= 19818. Available at : http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId= 19818. Accessed 5 November 2011.
37. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Malden, MA: Blackwell Science Ltd., 1998:222.
38. Skowronski DM, Hottes TS, De Serres G, et al. Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Ped Infect Dis J 2011; 30:833-9.
39. Gilca V, De Serres G, Hamelin M-E, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 2011; 30:35-41.
40. Irving SA, Donahue JG, Shay DK, Ellis-Coyle TL, Belongia EA. Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine 2009; 27:6546-9.